CME Group Inc. reported significant financial growth for the quarter and nine months ended September 30, 2024, compared to the same periods in 2023. Total revenues for Q3 2024 reached $1,584.4 million, an 18% increase from $1,337.8 million in Q3 2023. For the nine months, revenues rose to $4,604.8 million from $4,139.6 million, reflecting a strong performance in clearing and transaction fees, which increased to $1,297.1 million in Q3 2024 from $1,085.5 million in Q3 2023, and to $3,755.9 million for the nine months, up from $3,404.0 million.
Net income for Q3 2024 was $912.8 million, up from $750.2 million in Q3 2023, while net income for the nine months increased to $2,651.2 million from $2,411.6 million. Earnings per share attributable to common shareholders also improved, with Q3 2024 figures at $2.51 compared to $2.06 in Q3 2023, and $7.29 for the nine months, up from $6.63.
CME Group's total assets grew to $137,795.1 million as of September 30, 2024, from $129,706.1 million at the end of 2023. Current assets increased to $103,142.8 million, while current liabilities rose to $100,821.8 million. Long-term debt decreased significantly from $3,425.4 million to $2,677.7 million, contributing to an increase in total shareholders' equity from $26,737.9 million to $28,216.2 million.
Investment income for Q3 2024 was $1,026.8 million, down 19% from $1,272.5 million in Q3 2023, and for the nine months, it decreased to $3,142.6 million from $4,198.4 million. Earnings from cash performance bond and guaranty fund contributions also fell, totaling $991.3 million in Q3 2024 compared to $1,246.5 million in Q3 2023.
Operating expenses increased by $42.6 million in Q3 2024 and by $53.3 million for the nine months, primarily due to higher software license fees and increased headcount. However, depreciation and amortization expenses decreased, reflecting a decline in fixed asset purchases.
CME Group maintained a strong cash position with cash and cash equivalents totaling $2.3 billion as of September 30, 2024, down from $2.9 billion at the end of 2023. The company declared a quarterly dividend of $1.15 per share on November 7, 2024, totaling approximately $420 million, payable on December 27, 2024.
Overall, CME Group's performance in 2024 reflects robust revenue growth driven by increased trading volumes and effective management of expenses, despite declines in investment income and earnings from performance bond contributions.
About CME GROUP INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.